Literature DB >> 18836290

Epigenetic changes in gliomas.

Rebecca Burgess1, Robert Jenkins, Zhiguo Zhang.   

Abstract

Epigenetics are defined, in broad-terms, as alterations in gene expression without changes in DNA sequence. While histone modifications and DNA methylation are two classical means to regulate gene expression, miRNA has also recently been documented to govern gene expression in normal as well as cancer cells. In this review, we will first describe briefly histone modifications, DNA methylation and miRNAs and the functions of these epigenetic marks during different cellular processes involving DNA metabolism. We will then highlight some epigenetic changes in glioblastomas, a malignant form of brain tumor, and potential application of epigenetic means for diagnosis, prognosis, and treatment of gliomas. We expect that novel therapies will be developed to counter epigenetic changes in this deadly disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18836290      PMCID: PMC2954629          DOI: 10.4161/cbt.7.9.6992

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  122 in total

Review 1.  The diverse functions of histone acetyltransferase complexes.

Authors:  Michael J Carrozza; Rhea T Utley; Jerry L Workman; Jacques Côté
Journal:  Trends Genet       Date:  2003-06       Impact factor: 11.639

Review 2.  Epigenetics: a landscape takes shape.

Authors:  Aaron D Goldberg; C David Allis; Emily Bernstein
Journal:  Cell       Date:  2007-02-23       Impact factor: 41.582

Review 3.  Histone acetylation and deacetylation in yeast.

Authors:  Siavash K Kurdistani; Michael Grunstein
Journal:  Nat Rev Mol Cell Biol       Date:  2003-04       Impact factor: 94.444

Review 4.  The epigenomics of cancer.

Authors:  Peter A Jones; Stephen B Baylin
Journal:  Cell       Date:  2007-02-23       Impact factor: 41.582

5.  Distinct methylation profiles of glioma subtypes.

Authors:  Karen Uhlmann; Klaus Rohde; Constanze Zeller; Janusz Szymas; Siegfried Vogel; Karola Marczinek; Gundula Thiel; Peter Nürnberg; Peter W Laird
Journal:  Int J Cancer       Date:  2003-08-10       Impact factor: 7.396

6.  Promoter hypermethylation of multiple genes in astrocytic gliomas.

Authors:  Pilar Gonzalez-Gomez; M Josefa Bello; Dolores Arjona; Jesus Lomas; M Eva Alonso; Jose M De Campos; Jesus Vaquero; Alberto Isla; Manuel Gutierrez; Juan A Rey
Journal:  Int J Oncol       Date:  2003-03       Impact factor: 5.650

7.  Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms.

Authors:  Michael G House; James G Herman; Ming Zhou Guo; Craig M Hooker; Richard D Schulick; Keith D Lillemoe; John L Cameron; Ralph H Hruban; Anirban Maitra; Charles J Yeo
Journal:  Ann Surg       Date:  2003-09       Impact factor: 12.969

8.  Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human glioma cells.

Authors:  Santhi D Konduri; Kalkunte S Srivenugopal; Niranjan Yanamandra; Dzung H Dinh; William C Olivero; Meena Gujrati; Donald C Foster; Walter Kisiel; Francis Ali-Osman; Shakuntala Kondraganti; Sajani S Lakka; Jasti S Rao
Journal:  Oncogene       Date:  2003-07-17       Impact factor: 9.867

9.  Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene.

Authors:  Kurtis E Bachman; Ben Ho Park; Ina Rhee; Harith Rajagopalan; James G Herman; Stephen B Baylin; Kenneth W Kinzler; Bert Vogelstein
Journal:  Cancer Cell       Date:  2003-01       Impact factor: 31.743

10.  Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas.

Authors:  Chiaki Komine; Takao Watanabe; Yoichi Katayama; Atsuo Yoshino; Takakazu Yokoyama; Takao Fukushima
Journal:  Brain Pathol       Date:  2003-04       Impact factor: 6.508

View more
  13 in total

1.  RARβ gene methylation is a candidate for primary glioblastoma treatment planning.

Authors:  Emine İkbal Atli; Rasime Kalkan; Muhsin Özdemir; Hasan Emre Aydın; Ali Arslantaş; Sevilhan Artan
Journal:  Afr Health Sci       Date:  2016-03       Impact factor: 0.927

2.  Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth.

Authors:  Mark Katakowski; Ben Buller; Xuguang Zheng; Yong Lu; Thomas Rogers; Oyinkansola Osobamiro; Wayne Shu; Feng Jiang; Michael Chopp
Journal:  Cancer Lett       Date:  2013-02-16       Impact factor: 8.679

3.  Methylation and expression patterns of tropomyosin-related kinase genes in different grades of glioma.

Authors:  Mahalakshmi Palani; R Arunkumar; Arrambakam Janardhanam Vanisree
Journal:  Neuromolecular Med       Date:  2014-05-20       Impact factor: 3.843

4.  Detecting the H3F3A mutant allele found in high-grade pediatric glioma by real-time PCR.

Authors:  Ray Zhang; Jing Han; David Daniels; Haojie Huang; Zhiguo Zhang
Journal:  J Neurooncol       Date:  2015-09-16       Impact factor: 4.130

5.  Mechanism-anchored profiling derived from epigenetic networks predicts outcome in acute lymphoblastic leukemia.

Authors:  Xinan Yang; Yong Huang; James L Chen; Jianming Xie; Xiao Sun; Yves A Lussier
Journal:  BMC Bioinformatics       Date:  2009-09-17       Impact factor: 3.169

Review 6.  Regulation of non-coding RNA networks in the nervous system--what's the REST of the story?

Authors:  Irfan A Qureshi; Mark F Mehler
Journal:  Neurosci Lett       Date:  2009-08-11       Impact factor: 3.046

7.  Salinomycin-loaded Nanofibers for Glioblastoma Therapy.

Authors:  Mohammad Norouzi; Zahra Abdali; Song Liu; Donald W Miller
Journal:  Sci Rep       Date:  2018-06-20       Impact factor: 4.379

8.  DNA methylation, histone modifications, and signal transduction pathways: a close relationship in malignant gliomas pathophysiology.

Authors:  Raúl Alelú-Paz; Nadia Ashour; Ana González-Corpas; Santiago Ropero
Journal:  J Signal Transduct       Date:  2012-07-17

Review 9.  Anti-Transcription Factor RNA Aptamers as Potential Therapeutics.

Authors:  Estefanía Mondragón; Louis James Maher
Journal:  Nucleic Acid Ther       Date:  2015-10-28       Impact factor: 5.486

10.  Integrator complex subunit 6 (INTS6) inhibits hepatocellular carcinoma growth by Wnt pathway and serve as a prognostic marker.

Authors:  Ka Yin Lui; Hui Zhao; Chunhui Qiu; Chuo Li; Zhigang Zhang; Haoran Peng; Rongdang Fu; Hu-An Chen; Min-Qiang Lu
Journal:  BMC Cancer       Date:  2017-09-12       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.